Procysbi Granule, Delayed Release
Product Images NDC 75987-140

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Procysbi (NDC 75987-140). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Horizon Therapeutics Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Procysbi 01)

Chemical structure of cysteamine bitartrate, the active ingredient in PROCYSBI. The diagram shows the molecular arrangement of cysteamine attached to a bitartrate group, indicating various functional groups including amine, thiol, hydroxyl, and carboxyl groups.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

PROCYSBI 25 mg delayed-release capsules label showing active ingredient cysteamine bitartrate. The label indicates the package contains 60 capsules. It includes storage instructions, dispensing information, and the distributor Horizon Therapeutics USA, Inc. The label features a barcode and states the country of origin as Italy.*

FDA Label Image

Principal Display Panel (75 mg Capsule Bottle Label)

The label for PROCYSBI 75 mg delayed-release capsules contains 250 capsules and indicates the active ingredient cysteamine bitartrate equivalent to 75 mg cysteamine per capsule. It includes storage instructions to refrigerate prior to dispensing and to store at room temperature afterward, with a 4-month expiration post dispensing. Distributed by Horizon Therapeutics USA, Inc., Deerfield, IL, with country of origin Italy, the label features a barcode and Rx Only designation.*

FDA Label Image

Procysbi 04

PROCYSBI 75 mg delayed-release oral granules packaging label shows the brand name and generic name cysteamine bitartrate. The label indicates a package contains 60 packets and states to dispense only in original packaging. Labeler information is Horizon Therapeutics USA, Inc. Instructions include storage and dispensing precautions, with a purple and white color scheme and product identification barcodes.*

FDA Label Image

Procysbi 05

PROCYSBI 300 mg delayed-release oral granules in packet form by Horizon Therapeutics USA, Inc. The label states the active ingredient as cysteamine bitartrate and includes storage instructions, patient warnings, and a discard after date box. The packaging contains 60 packets and notes that each packet contains 884 mg cysteamine bitartrate equivalent to 300 mg cysteamine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.